IRIDEX (NASDAQ:IRIX) Stock: Insider Shih-Yao David Lin Purchases 50,000 Shares

Posted by Stanley Muller on Oct 9th, 2026

IRIDEX Corporation (NASDAQ:IRIX – Get Free Report) major shareholder Shih-Yao David Lin acquired 50,000 shares of the business’s stock in a transaction on Friday, June 27th. The shares were purchased at an average price of $0.89 per share, with a total value of $44,500.00. Following the completion of the purchase, the insider owned 675,667 shares in the company, valued at $601,343.63. This represents a 7.99% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Major shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

IRIDEX Price Performance

Shares of IRIDEX stock opened at $0.90 on Friday. The stock has a market capitalization of $15.78 million, a P/E ratio of -4.49 and a beta of 0.67. The business has a 50 day simple moving average of $0.73 and a two-hundred day simple moving average of $0.95. IRIDEX Corporation has a 12 month low of $0.61 and a 12 month high of $1.65.

IRIDEX (NASDAQ:IRIX – Get Free Report) last issued its quarterly earnings results on Tuesday, August 18th. The medical equipment provider reported ($0.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.06). The firm had revenue of $12.57 million during the quarter, compared to analysts’ expectations of $13.59 million. As a group, research analysts anticipate that IRIDEX Corporation will post -0.12 EPS for the current fiscal year.

Key Stories Impacting IRIDEX

Here are the key news stories impacting IRIDEX this week:

Positive Sentiment: Lin reported another purchase of 10,000 IRIX shares at an average price of $1.05, worth $10,500. The transaction increased his direct holdings to 735,561 shares. IRIDEX major shareholder buys 10,000 shares
Positive Sentiment: SEC disclosures show a sustained accumulation campaign by Lin, including purchases of 50,000 shares at $0.99, 40,114 shares at $1.00 and 80,000 shares at $1.00, along with numerous other transactions. Repeated buying by a major shareholder may signal confidence in IRIDEX’s longer-term prospects and can support momentum in a low-market-cap stock. IRIDEX major shareholder buys 50,000 shares
Positive Sentiment: Several institutional investors also increased positions, including Perkins Capital Management, Thompson Davis, and Renaissance Technologies. Institutions own approximately 20.1% of IRIDEX’s shares, providing additional ownership support, though their disclosed positions remain relatively small in dollar terms.
Neutral Sentiment: Trading in IRIX was temporarily halted under a Limit Up-Limit Down pause. The halt underscores unusually high volatility and the possibility of sharp price reversals when trading resumes.
Neutral Sentiment: Analyst sentiment remains mixed: one analyst rates the stock Buy and another Sell, resulting in a consensus Hold rating. The reported consensus price target is $3.00, but the limited coverage reduces its reliability.
Negative Sentiment: IRIDEX’s latest reported quarter remains a fundamental concern. The company posted a $0.07-per-share loss versus a $0.01 expected loss and revenue of $12.57 million versus the $13.59 million consensus estimate. Analysts expect a full-year loss of approximately $0.12 per share.

Analyst Ratings Changes

Separately, Weiss Ratings raised shares of IRIDEX from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, October 2nd. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $3.00.

Check Out Our Latest Report on IRIDEX

Hedge Funds Weigh In On IRIDEX

Several institutional investors and hedge funds have recently bought and sold shares of the company. Perkins Capital Management Inc. increased its holdings in shares of IRIDEX by 33.9% during the 1st quarter. Perkins Capital Management Inc. now owns 55,300 shares of the medical equipment provider’s stock worth $56,000 after buying an additional 14,000 shares during the last quarter. Thompson Davis & CO. Inc. lifted its holdings in IRIDEX by 66.5% in the first quarter. Thompson Davis & CO. Inc. now owns 47,444 shares of the medical equipment provider’s stock valued at $48,000 after acquiring an additional 18,944 shares during the last quarter. Renaissance Technologies LLC lifted its holdings in IRIDEX by 6.7% in the first quarter. Renaissance Technologies LLC now owns 396,627 shares of the medical equipment provider’s stock valued at $401,000 after acquiring an additional 25,067 shares during the last quarter. Bank of New York Mellon Corp purchased a new position in IRIDEX in the second quarter worth approximately $29,000. Finally, Diversify Wealth Management LLC purchased a new position in IRIDEX in the first quarter worth approximately $35,000. 20.10% of the stock is currently owned by institutional investors and hedge funds.

About IRIDEX

(Get Free Report)

IRIDEX Corporation (NASDAQ: IRIX) develops and sells ophthalmic laser systems and related delivery devices used in the treatment of eye diseases. Its products are designed primarily for ophthalmologists treating glaucoma and retinal disorders, including diabetic retinopathy and other conditions affecting the retina.

The company’s portfolio includes laser systems such as the Cyclo G6 glaucoma laser platform and the IQ series of retinal photocoagulation lasers. IRIDEX also offers specialized probes and other delivery devices, including MicroPulse and transscleral cyclophotocoagulation technologies, which are intended to provide targeted treatment while limiting exposure to surrounding tissue.

Founded in 1989 and headquartered in Mountain View, California, IRIDEX serves eye-care professionals through a combination of direct sales and distributor relationships in the United States and international markets.